Share-based Payment Arrangement, Expense of ALNYLAM PHARMACEUTICALS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ALNYLAM PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • ALNYLAM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $108,211,000, a 136% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $368,248,000, a 66% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $272,084,000, a 23% increase from 2023.
  • ALNYLAM PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $221,680,000, a 3.9% decline from 2022.
  • ALNYLAM PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $230,649,000, a 39% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $368,248,000 $108,211,000 +$62,407,000 +136% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $305,841,000 $111,680,000 +$22,392,000 +25% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $283,449,000 $56,712,000 +$11,365,000 +25% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $272,084,000 $91,645,000 +$49,651,000 +118% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $222,433,000 $45,804,000 -$18,133,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $240,566,000 $89,288,000 +$13,486,000 +18% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2025 2025 Q2
Q1 2024 $227,080,000 $45,347,000 +$5,400,000 +14% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $221,680,000 $41,994,000 -$773,000 -1.8% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $222,453,000 $63,937,000 -$64,181,000 -50% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $286,634,000 $75,802,000 +$45,331,000 +149% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $241,303,000 $39,947,000 +$10,654,000 +36% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $230,649,000 $42,767,000 -$1,815,000 -4.1% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $232,464,000 $128,118,000 +$94,751,000 +284% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $137,713,000 $30,471,000 -$1,607,000 -5% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $139,320,000 $29,293,000 -$26,397,000 -47% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $165,717,000 $44,582,000 +$10,306,000 +30% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $155,411,000 $33,367,000 -$3,897,000 -10% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022 2022 Q3
Q2 2021 $159,308,000 $32,078,000 -$1,677,000 -5% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022 2022 Q2
Q1 2021 $160,985,000 $55,690,000 +$21,112,000 +61% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q4 2020 $139,873,000 $34,276,000 -$31,921,000 -48% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $171,794,000 $37,264,000 -$8,745,000 -19% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $180,539,000 $33,755,000 +$3,152,000 +10% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $177,387,000 $34,578,000 +$2,546,000 +7.9% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $174,841,000 $66,197,000 +$38,224,000 +137% 01 Oct 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
Q3 2019 $136,617,000 $46,009,000 -$41,945,000 -48% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $178,562,000 $30,603,000 +$8,362,000 +38% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $170,200,000 $32,032,000 +$12,448,000 +64% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $157,752,000 $27,973,000 01 Oct 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
Q3 2018 $87,954,000 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $22,241,000 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $19,584,000 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1

ALNYLAM PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $272,084,000 +$50,404,000 +23% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $221,680,000 -$8,969,000 -3.9% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $230,649,000 +$64,932,000 +39% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $165,717,000 +$25,844,000 +18% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $139,873,000 -$34,968,000 -20% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $174,841,000 +$17,089,000 +11% 01 Jan 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
2018 $157,752,000 +$64,933,000 +70% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $92,819,000 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2012 $12,700,000 -$4,400,000 -26% 01 Jan 2012 31 Dec 2012 10-K 19 Feb 2013 2012 FY
2011 $17,100,000 -$2,300,000 -12% 01 Jan 2011 31 Dec 2011 10-K 19 Feb 2013 2012 FY
2010 $19,400,000 01 Jan 2010 31 Dec 2010 10-K 19 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.